Insider transactions

EDGAR

Chanticleer Holdings, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-22.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–17 of 17

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2025-12-02 Filed 2025-12-04Kenney Richard T Officer: Chief Medical Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)9,374——0Direct (D) No
F1, F2, F7
  • F1 On December 2, 2025, pursuant to the Business Combination Agreement (the BCA), dated July 11, 2025, by and among Sonnet BioTherapeutics Holdings, Inc. (the Company), Rorschach I LLC (Rorschach), Hyperliquid Strategies Inc (HSI), TBS Merger Sub Inc (Company Merger Sub) and Rorschach Merger Sub, LLC (Rorschach Merger Sub), Rorschach Merger Sub merged with and into Rorschach with Rorschach surviving the merger as a direct wholly owned subsidiary of HSI and immediately following such merger, Company Merger Sub merged with and into the Company with the Company surviving the merger as a direct wholly owned subsidiary of HSI (the Company Merger).
  • F2 (Continued from footnote 1) Includes (i) 8,000 restricted stock units granted on July 11, 2025 which, as a result of the Company Merger, vested at the Effective Time and (ii) 1,374 vested restricted stock units held by the Reporting Person at the Effective Time. Pursuant to the BCA, each restricted stock unit was exchanged at the Effective Time for (i) one-fifth of a share of HSI Common Stock and (ii) one CVR.
  • F7 All amounts reflect the Company's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024.
Open filing 0001493152-25-026217 Read from the filing’s XML Dispute this row
2025-12-02 Filed 2025-12-04Kenney Richard T Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)86,505——86,505Direct (D) No
F3, F4
  • F3 On June 30, 2025, the Reporting Person was issued warrants to purchase up to 86,505 shares of Company Common Stock as partial consideration for a convertible note (the Convertible Note) issued by the Company in favor of the Reporting Person in the principal amount of $200,000. The Convertible Note and warrants cannot be converted or exercised, respectively, to the extent that, after giving effect to such conversion or exercise, the Reporting Person would beneficially own in excess of 4.99% of the then issued and outstanding shares of Company Common Stock. At the Effective Time, the warrants were automatically exercised on a cashless basis pursuant to the terms of the warrants, and exchanged for (i) one-fifth of a share of HSI Common Stock and (ii) one CVR.
  • F4 (Continued from footnote 3) In connection with the cashless exercise, the Company withheld shares to pay the exercise price, based on a fair market value of $4.764 per share.
Open filing 0001493152-25-026217 Read from the filing’s XML Dispute this row
2025-12-02 Filed 2025-12-04Kenney Richard T Officer: Chief Medical Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)16,891——69,614Direct (D) No
F3, F4
  • F3 On June 30, 2025, the Reporting Person was issued warrants to purchase up to 86,505 shares of Company Common Stock as partial consideration for a convertible note (the Convertible Note) issued by the Company in favor of the Reporting Person in the principal amount of $200,000. The Convertible Note and warrants cannot be converted or exercised, respectively, to the extent that, after giving effect to such conversion or exercise, the Reporting Person would beneficially own in excess of 4.99% of the then issued and outstanding shares of Company Common Stock. At the Effective Time, the warrants were automatically exercised on a cashless basis pursuant to the terms of the warrants, and exchanged for (i) one-fifth of a share of HSI Common Stock and (ii) one CVR.
  • F4 (Continued from footnote 3) In connection with the cashless exercise, the Company withheld shares to pay the exercise price, based on a fair market value of $4.764 per share.
Open filing 0001493152-25-026217 Read from the filing’s XML Dispute this row
2025-12-02 Filed 2025-12-04Kenney Richard T Officer: Chief Medical Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)69,614——0Direct (D) No
F3, F4
  • F3 On June 30, 2025, the Reporting Person was issued warrants to purchase up to 86,505 shares of Company Common Stock as partial consideration for a convertible note (the Convertible Note) issued by the Company in favor of the Reporting Person in the principal amount of $200,000. The Convertible Note and warrants cannot be converted or exercised, respectively, to the extent that, after giving effect to such conversion or exercise, the Reporting Person would beneficially own in excess of 4.99% of the then issued and outstanding shares of Company Common Stock. At the Effective Time, the warrants were automatically exercised on a cashless basis pursuant to the terms of the warrants, and exchanged for (i) one-fifth of a share of HSI Common Stock and (ii) one CVR.
  • F4 (Continued from footnote 3) In connection with the cashless exercise, the Company withheld shares to pay the exercise price, based on a fair market value of $4.764 per share.
Open filing 0001493152-25-026217 Read from the filing’s XML Dispute this row
2025-12-02 Filed 2025-12-04Kenney Richard T Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)163,760——163,760Direct (D) No
F6
  • F6 On July 14, the Reporting Person was issued 200 shares of Series 5 Preferred Stock, initially convertible at a conversion price of $1.25 per share upon the conversion in full of the Convertible Note. The Series 5 Preferred Stock cannot be converted to the extent that, after giving effect to such conversion, the Reporting Person would beneficially own in excess of 4.99% of the then issued and outstanding shares of Common Stock. The Series 5 Preferred Stock is perpetual and therefore has no expiration date. Pursuant to the BCA, at the Effective Time, each share of Series 5 Preferred Stock was automatically converted into such number of Company Common Stock determined by dividing the stated value of such share of Series 5 Preferred Stock plus all unpaid accrued and accumulated Preferential Dividends on such share (whether or not declared) by the Conversion Price of $1.25, and exchanged for one-fifth of a share of HSI Common Stock.
Open filing 0001493152-25-026217 Read from the filing’s XML Dispute this row
2025-12-02 Filed 2025-12-04Kenney Richard T Officer: Chief Medical Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)163,760——0Direct (D) No
F6
  • F6 On July 14, the Reporting Person was issued 200 shares of Series 5 Preferred Stock, initially convertible at a conversion price of $1.25 per share upon the conversion in full of the Convertible Note. The Series 5 Preferred Stock cannot be converted to the extent that, after giving effect to such conversion, the Reporting Person would beneficially own in excess of 4.99% of the then issued and outstanding shares of Common Stock. The Series 5 Preferred Stock is perpetual and therefore has no expiration date. Pursuant to the BCA, at the Effective Time, each share of Series 5 Preferred Stock was automatically converted into such number of Company Common Stock determined by dividing the stated value of such share of Series 5 Preferred Stock plus all unpaid accrued and accumulated Preferential Dividends on such share (whether or not declared) by the Conversion Price of $1.25, and exchanged for one-fifth of a share of HSI Common Stock.
Open filing 0001493152-25-026217 Read from the filing’s XML Dispute this row
2025-12-02 Filed 2025-12-04Kenney Richard T Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Warrant (Common Stock) — underlying Common Stock — exercise price 1.156
Disposed (D)86,505——0Direct (D) No
F3, F8
  • F3 On June 30, 2025, the Reporting Person was issued warrants to purchase up to 86,505 shares of Company Common Stock as partial consideration for a convertible note (the Convertible Note) issued by the Company in favor of the Reporting Person in the principal amount of $200,000. The Convertible Note and warrants cannot be converted or exercised, respectively, to the extent that, after giving effect to such conversion or exercise, the Reporting Person would beneficially own in excess of 4.99% of the then issued and outstanding shares of Company Common Stock. At the Effective Time, the warrants were automatically exercised on a cashless basis pursuant to the terms of the warrants, and exchanged for (i) one-fifth of a share of HSI Common Stock and (ii) one CVR.
  • F8 Represents securities previously acquired in transactions exempt under Rule 16b-3.
Open filing 0001493152-25-026217 Read from the filing’s XML Dispute this row
2025-12-02 Filed 2025-12-04Kenney Richard T Officer: Chief Medical Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Warrant (Common Stock) — underlying Common Stock — exercise price 1.25
Disposed (D)320,000——0Direct (D) No
F5, F8
  • F5 On July 14, 2025, the Reporting Person was issued warrants to purchase up to 320,000 shares of Company Common Stock upon the conversion in full of the Convertible Note. The warrants cannot be exercised to the extent that, after giving effect to such exercise, the Reporting Person would beneficially own in excess of 4.99% of the then issued and outstanding shares of Common Stock. Pursuant to the BCA, at the Effective Time, the warrants shall (a) cease to represent a warrant in respect of shares of Company Common Stock and shall be assumed by HSI and automatically converted into a warrant to acquire the same number of shares of HSI Common Stock, subject to the same terms and conditions immediately prior to the Effective Time or (b) entitle the holder of warrant to such other consideration that such holder is entitled to receive pursuant to the terms of such warrant.
  • F8 Represents securities previously acquired in transactions exempt under Rule 16b-3.
Open filing 0001493152-25-026217 Read from the filing’s XML Dispute this row
2025-12-02 Filed 2025-12-04Kenney Richard T Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Series 5 Preferred Stock — underlying Common Stock — exercise price 1.25
Disposed (D)200——0Direct (D) No
F6, F8
  • F6 On July 14, the Reporting Person was issued 200 shares of Series 5 Preferred Stock, initially convertible at a conversion price of $1.25 per share upon the conversion in full of the Convertible Note. The Series 5 Preferred Stock cannot be converted to the extent that, after giving effect to such conversion, the Reporting Person would beneficially own in excess of 4.99% of the then issued and outstanding shares of Common Stock. The Series 5 Preferred Stock is perpetual and therefore has no expiration date. Pursuant to the BCA, at the Effective Time, each share of Series 5 Preferred Stock was automatically converted into such number of Company Common Stock determined by dividing the stated value of such share of Series 5 Preferred Stock plus all unpaid accrued and accumulated Preferential Dividends on such share (whether or not declared) by the Conversion Price of $1.25, and exchanged for one-fifth of a share of HSI Common Stock.
  • F8 Represents securities previously acquired in transactions exempt under Rule 16b-3.
Open filing 0001493152-25-026217 Read from the filing’s XML Dispute this row
2025-12-02 Filed 2025-12-03MCANDREW STEPHEN J Officer: Chief Business Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)6,446——0Direct (D) No
F1, F2, F3
  • F1 On December 2, 2025, pursuant to the Business Combination Agreement (the BCA), dated July 11, 2025, by and among Sonnet BioTherapeutics Holdings, Inc. (the Company), Rorschach I LLC (Rorschach), Hyperliquid Strategies Inc (HSI), TBS Merger Sub Inc (Company Merger Sub) and Rorschach Merger Sub, LLC (Rorschach Merger Sub), Rorschach Merger Sub merged with and into Rorschach with Rorschach surviving the merger as a direct wholly owned subsidiary of HSI and immediately following such merger, Company Merger Sub merged with and into the Company with the Company surviving the merger as a direct wholly owned subsidiary of HSI (the Company Merger).
  • F2 (Continued from footnote 1) Includes (i) 6,000 restricted stock units granted on July 11, 2025 which, as a result of the Company Merger, vested at the Effective Time and (ii) 446 vested restricted stock units held by the Reporting Person at the Effective Time. Pursuant to the BCA, each restricted stock unit was exchanged at the Effective Time for (i) one-fifth of a share of HSI Common Stock and (ii) one CVR.
  • F3 All amounts reflect the Company's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024.
Open filing 0001493152-25-026069 Read from the filing’s XML Dispute this row
2025-12-02 Filed 2025-12-03Dyrness Albert D. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)4,537——0Direct (D) No
F1, F2, F3
  • F1 On December 2, 2025, pursuant to the Business Combination Agreement (the BCA), dated July 11, 2025, by and among Sonnet BioTherapeutics Holdings, Inc. (the Company), Rorschach I LLC (Rorschach), Hyperliquid Strategies Inc (HSI), TBS Merger Sub Inc (Company Merger Sub) and Rorschach Merger Sub, LLC (Rorschach Merger Sub), Rorschach Merger Sub merged with and into Rorschach with Rorschach surviving the merger as a direct wholly owned subsidiary of HSI and immediately following such merger, Company Merger Sub merged with and into the Company with the Company surviving the merger as a direct wholly owned subsidiary of HSI (the Company Merger).
  • F2 (Continued from footnote 1) Includes (i) 4,000 restricted stock units granted on July 11, 2025 which, as a result of the Company Merger, vested at the Effective Time and (ii) 537 vested restricted stock units held by the Reporting Person at the Effective Time. Pursuant to the BCA, each restricted stock unit was exchanged at the Effective Time for (i) one-fifth of a share of HSI Common Stock and (ii) one CVR.
  • F3 All amounts reflect the Company's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024.
Open filing 0001493152-25-026062 Read from the filing’s XML Dispute this row
2025-12-02 Filed 2025-12-03Dexter Susan Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)9,643——0Direct (D) No
F1, F2, F3
  • F1 . On December 2, 2025, pursuant to the Business Combination Agreement (the BCA), dated July 11, 2025, by and among Sonnet BioTherapeutics Holdings, Inc. (the Company), Rorschach I LLC (Rorschach), Hyperliquid Strategies Inc (HSI), TBS Merger Sub Inc (Company Merger Sub) and Rorschach Merger Sub, LLC (Rorschach Merger Sub), Rorschach Merger Sub merged with and into Rorschach with Rorschach surviving the merger as a direct wholly owned subsidiary of HSI and immediately following such merger, Company Merger Sub merged with and into the Company with the Company surviving the merger as a direct wholly owned subsidiary of HSI (the Company Merger).
  • F2 (Continued from footnote 1) Includes (i) 8,000 restricted stock units granted on July 11, 2025 which, as a result of the Company Merger, vested at the Effective Time and (ii) 1,643 vested restricted stock units held by the Reporting Person at the Effective Time. Pursuant to the BCA, each restricted stock unit was exchanged at the Effective Time for (i) one-fifth of a share of HSI Common Stock and (ii) one CVR.
  • F3 All amounts reflect the Company's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024.
Open filing 0001493152-25-026068 Read from the filing’s XML Dispute this row
2025-12-02 Filed 2025-12-03McNeill Lori Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)4,394——0Direct (D) No
F1, F2, F3
  • F1 On December 2, 2025, pursuant to the Business Combination Agreement (the BCA), dated July 11, 2025, by and among Sonnet BioTherapeutics Holdings, Inc. (the Company), Rorschach I LLC (Rorschach), Hyperliquid Strategies Inc (HSI), TBS Merger Sub Inc (Company Merger Sub) and Rorschach Merger Sub, LLC (Rorschach Merger Sub), Rorschach Merger Sub merged with and into Rorschach with Rorschach surviving the merger as a direct wholly owned subsidiary of HSI and immediately following such merger, Company Merger Sub merged with and into the Company with the Company surviving the merger as a direct wholly owned subsidiary of HSI (the Company Merger).
  • F2 (Continued from footnote 1) Includes (i) 4,000 restricted stock units granted on July 11, 2025 which, as a result of the Company Merger, vested at the Effective Time and (ii) 394 vested restricted stock units held by the Reporting Person at the Effective Time. Pursuant to the BCA, each restricted stock unit was exchanged at the Effective Time for (i) one-fifth of a share of HSI Common Stock and (ii) one CVR.
  • F3 All amounts reflect the Company's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024.
Open filing 0001493152-25-026065 Read from the filing’s XML Dispute this row
2025-12-02 Filed 2025-12-03Cini John K. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)14,116——0Direct (D) No
F1, F2, F3
  • F1 On December 2, 2025, pursuant to the Business Combination Agreement (the BCA), dated July 11, 2025, by and among Sonnet BioTherapeutics Holdings, Inc. (the Company), Rorschach I LLC (Rorschach), Hyperliquid Strategies Inc (HSI), TBS Merger Sub Inc (Company Merger Sub) and Rorschach Merger Sub, LLC (Rorschach Merger Sub), Rorschach Merger Sub merged with and into Rorschach with Rorschach surviving the merger as a direct wholly owned subsidiary of HSI and immediately following such merger, Company Merger Sub merged with and into the Company with the Company surviving the merger as a direct wholly owned subsidiary of HSI (the Company Merger).
  • F2 (Continued from footnote 1) Includes (i) 12,000 restricted stock units granted on July 11, 2025 which, as a result of the Company Merger, vested at the Effective Time and (ii) 2,116 vested restricted stock units held by the Reporting Person at the Effective Time. Pursuant to the BCA, each restricted stock unit was exchanged at the Effective Time for (i) one-fifth of a share of HSI Common Stock and (ii) one CVR.
  • F3 All amounts reflect the Company's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024.
Open filing 0001493152-25-026064 Read from the filing’s XML Dispute this row
2025-12-02 Filed 2025-12-03Bhatt Nailesh Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)10,547——0Direct (D) No
F1, F2, F3
  • F1 On December 2, 2025, pursuant to the Business Combination Agreement (the BCA), dated July 11, 2025, by and among Sonnet BioTherapeutics Holdings, Inc. (the Company), Rorschach I LLC (Rorschach), Hyperliquid Strategies Inc (HSI), TBS Merger Sub Inc (Company Merger Sub) and Rorschach Merger Sub, LLC (Rorschach Merger Sub), Rorschach Merger Sub merged with and into Rorschach with Rorschach surviving the merger as a direct wholly owned subsidiary of HSI and immediately following such merger, Company Merger Sub merged with and into the Company with the Company surviving the merger as a direct wholly owned subsidiary of HSI (the Company Merger).
  • F2 (Continued from footnote 1) Includes (i) 10,000 restricted stock units granted on July 11, 2025 which, as a result of the Company Merger, vested at the Effective Time and (ii) 547 vested restricted stock units held by the Reporting Person at the Effective Time. Pursuant to the BCA, each restricted stock unit was exchanged at the Effective Time for (i) one-fifth of a share of HSI Common Stock and (ii) one CVR.
  • F3 All amounts reflect the Company's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024.
Open filing 0001493152-25-026066 Read from the filing’s XML Dispute this row
2025-12-02 Filed 2025-12-03Griffith Donald J. Director · Officer: Chief Financial Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)10,375——0Direct (D) No
F1, F2, F3
  • F1 On December 2, 2025, pursuant to the Business Combination Agreement (the BCA), dated July 11, 2025, by and among Sonnet BioTherapeutics Holdings, Inc. (the Company), Rorschach I LLC (Rorschach), Hyperliquid Strategies Inc (HSI), TBS Merger Sub Inc (Company Merger Sub) and Rorschach Merger Sub, LLC (Rorschach Merger Sub), Rorschach Merger Sub merged with and into Rorschach with Rorschach surviving the merger as a direct wholly owned subsidiary of HSI and immediately following such merger, Company Merger Sub merged with and into the Company with the Company surviving the merger as a direct wholly owned subsidiary of HSI (the Company Merger).
  • F2 (Continued from footnote 1) Includes (i) 10,000 restricted stock units granted on July 11, 2025 which, as a result of the Company Merger, vested at the Effective Time and (ii) 375 vested restricted stock units held by the Reporting Person at the Effective Time. Pursuant to the BCA, each restricted stock unit was exchanged at the Effective Time for (i) one-fifth of a share of HSI Common Stock and (ii) one CVR.
  • F3 All amounts reflect the Company's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024.
Open filing 0001493152-25-026063 Read from the filing’s XML Dispute this row
2025-12-02 Filed 2025-12-03Rao Raghu Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)22,356——0Direct (D) No
F1, F2, F3
  • F1 On December 2, 2025, pursuant to the Business Combination Agreement (the BCA), dated July 11, 2025, by and among Sonnet BioTherapeutics Holdings, Inc. (the Company), Rorschach I LLC (Rorschach), Hyperliquid Strategies Inc (HSI), TBS Merger Sub Inc (Company Merger Sub) and Rorschach Merger Sub, LLC (Rorschach Merger Sub), Rorschach Merger Sub merged with and into Rorschach with Rorschach surviving the merger as a direct wholly owned subsidiary of HSI and immediately following such merger, Company Merger Sub merged with and into the Company with the Company surviving the merger as a direct wholly owned subsidiary of HSI (the Company Merger).
  • F2 (Continued from footnote 1) Includes (i) 20,000 restricted stock units granted on July 11, 2025 which, as a result of the Company Merger, vested at the Effective Time and (ii) 2,356 vested restricted stock units held by the Reporting Person at the Effective Time. Pursuant to the BCA, each restricted stock unit was exchanged at the Effective Time for (i) one-fifth of a share of HSI Common Stock and (ii) one CVR.
  • F3 All amounts reflect the Company's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024.
Open filing 0001493152-25-026067 Read from the filing’s XML Dispute this row

Latest reported holdings

What each reporting owner last said they hold, as of the date shown. A transaction not yet filed is not in it.

Latest reported holdings
Reporting ownerSecurityShares owned afterDirect or indirectSource
Bhatt Nailesh DirectorCommon Stock 0D As of 2025-12-02 Open filing 4
Cini John K. DirectorCommon Stock 0D As of 2025-12-02 Open filing 4
Dexter Susan DirectorCommon Stock 0D As of 2025-12-02 Open filing 4
Dyrness Albert D. DirectorCommon Stock 0D As of 2025-12-02 Open filing 4
Griffith Donald J. Director · Officer: Chief Financial OfficerCommon Stock 0D As of 2025-12-02 Open filing 4
Kenney Richard T Officer: Chief Medical OfficerSeries 5 Preferred Stock Derivative security · underlying Common Stock0D As of 2025-12-02 Open filing 4
Kenney Richard T Officer: Chief Medical OfficerWarrant Derivative security · underlying Common Stock320,000D As of 2025-07-14 Open filing 4
Kenney Richard T Officer: Chief Medical OfficerWarrant (Common Stock) Derivative security · underlying Common Stock0D As of 2025-12-02 Open filing 4
Kenney Richard T Officer: Chief Medical OfficerCommon Stock 0D As of 2025-12-02 Open filing 4
MCANDREW STEPHEN J Officer: Chief Business OfficerCommon Stock 446D As of 2025-02-21 Open filing 3
MCANDREW STEPHEN J Officer: Chief Business OfficerCommon Stock 0D As of 2025-12-02 Open filing 4
McNeill Lori DirectorCommon Stock 0D As of 2025-12-02 Open filing 4
Mohan Pankaj Director · Officer: Chairman, President and CEOCommon Stock 3I By ChildAs of 2024-12-05 Open filing 4
Mohan Pankaj Director · Officer: Chairman, President and CEOCommon Stock 377I By Mohan Family OfficeAs of 2024-12-05 Open filing 4
Rao Raghu Director · Officer: Chief Executive OfficerCommon Stock 0D As of 2025-12-02 Open filing 4

Joint filers each report the same shares, so rows are not added together.

Institutional holders (Form 13F)

No Form 13F position in this issuer is placed in the store. A holder not yet linked or not yet filed is absent, not zero.

Institutional ownership reported on Form 13F

No percent is shown: the cover-page share count is not available for this company.

  • The lower figure counts positions a manager reports as its own with sole discretion. The upper figure counts every plain-share position and can count a share twice.
  • Neither includes holders that do not file Form 13F, or managers below the filing threshold.
Quarter-by-quarter 13F holders
QuarterManagers holdingShares, at leastShares, at mostFilings read
2026-09-30 0008,935
2026-06-30 0009,178
2026-03-31 0009,173
2025-12-31 137,18537,1859,222
2025-09-30 2920,657,82424,206,3318,469
2025-06-30 10133,622180,4068,516
2025-03-31 9133,622161,2638,518
2024-12-31 1019,23589,0708,580

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read from their tags. Earlier schedules are free text: they are read only when every cover page states a share count and a percent, and the rest are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Republic Digital Opportunistic Digital Assets Master Fund, Ltd. COM NEW4.2260,00007/14/2025 Filed 2025-07-25SCHEDULE 13GOpen filing 0000899140-25-000852 Dispute this row
Joseph Naggar COM NEW4.2260,00007/14/2025 Filed 2025-07-25SCHEDULE 13GOpen filing 0000899140-25-000852 Dispute this row
John Markey COM NEW6.5198,300— Filed 2024-01-02SC 13G/AAmendment 2Read from the cover page textOpen filing 0001948530-24-000002 Dispute this row
John Markey COM NEW7.6231,115— Filed 2023-11-17SC 13G/AAmendment 2Read from the cover page textOpen filing 0001948530-23-000015 Dispute this row
John Markey COM NEW6.4195,780— Filed 2023-11-06SC 13G/AAmendment 2Read from the cover page textOpen filing 0001948530-23-000014 Dispute this row
John Markey COM NEW10.74,100,000— Filed 2023-08-07SC 13G/AAmendment 2Read from the cover page textOpen filing 0001948530-23-000012 Dispute this row
John Markey COM NEW11.13,700,000— Filed 2023-07-17SC 13G/AAmendment 2Read from the cover page textOpen filing 0001948530-23-000011 Dispute this row
John Markey COM NEW9.93,305,000— Filed 2023-07-07SC 13G/AAmendment 2Read from the cover page textOpen filing 0001948530-23-000010 Dispute this row
John Markey COM NEW8.52,830,000— Filed 2023-06-30SC 13GAmendment 2Read from the cover page textOpen filing 0001948530-23-000009 Dispute this row
Matthew J. Ruck COM NEW6.181,700,000— Filed 2023-06-22SC 13G/AAmendment 2Read from the cover page textOpen filing 0001980840-23-000007 Dispute this row
Matthew J. Ruck COM NEW5.831,603,006— Filed 2023-06-14SC 13G/AAmendment 1Read from the cover page textOpen filing 0001980840-23-000005 Dispute this row
Matthew J. Ruck COM NEW5.831,603,006— Filed 2023-06-14SC 13G/AAmendment 1Read from the cover page textOpen filing 0001980840-23-000006 Dispute this row
John Markey COM NEW9.92,720,000— Filed 2023-06-12SC 13GAmendment 2Read from the cover page textOpen filing 0001948530-23-000005 Dispute this row
John Markey COM NEW8.42,300,000— Filed 2023-05-26SC 13G/AAmendment 2Read from the cover page textOpen filing 0001085146-23-002484 Dispute this row
John Markey COM NEW6.851,880,839— Filed 2023-05-17SC 13G/AAmendment 1Read from the cover page textOpen filing 0001085146-23-002469 Dispute this row
John Markey COM NEW6.51,320,507— Filed 2023-05-02SC 13GRead from the cover page textOpen filing 0001085146-23-002013 Dispute this row
Hudson Bay Capital Management LP Common Stock, par value $0.0001 per share2.97242,856— Filed 2023-02-10SC 13G/AAmendment 1Read from the cover page textOpen filing 0001393825-23-000170 Dispute this row
Sander Gerber Common Stock, par value $0.0001 per share2.97242,856— Filed 2023-02-10SC 13G/AAmendment 1Read from the cover page textOpen filing 0001393825-23-000170 Dispute this row
Hudson Bay Capital Management LP Common Stock, par value $0.0001 per share5.343,400,000— Filed 2022-02-03SC 13GRead from the cover page textOpen filing 0001393825-22-000047 Dispute this row
Sander Gerber Common Stock, par value $0.0001 per share5.343,400,000— Filed 2022-02-03SC 13GRead from the cover page textOpen filing 0001393825-22-000047 Dispute this row
Pankaj Mohan Common Stock, $0.0001 par value per share5.5942,959— Filed 2021-03-10SC 13GRead from the cover page textOpen filing 0000905718-21-000400 Dispute this row
Altium Capital Management, LP Common Stock, par value $0.0001 per share4.995,664,728— Filed 2021-02-16SC 13G/AAmendment 1Read from the cover page textOpen filing 0001387131-21-002387 Dispute this row
Altium Growth Fund, LP Common Stock, par value $0.0001 per share4.995,664,728— Filed 2021-02-16SC 13G/AAmendment 1Read from the cover page textOpen filing 0001387131-21-002387 Dispute this row
Altium Growth GP, LLC Common Stock, par value $0.0001 per share4.995,664,728— Filed 2021-02-16SC 13G/AAmendment 1Read from the cover page textOpen filing 0001387131-21-002387 Dispute this row
Empery Asset Management, LP Common Stock, $0.0001 par value4.995,707,107— Filed 2021-01-26SC 13G/AAmendment 1Read from the cover page textOpen filing 0000902664-21-000523 Dispute this row
Ryan M. Lane Common Stock, $0.0001 par value4.995,707,107— Filed 2021-01-26SC 13G/AAmendment 1Read from the cover page textOpen filing 0000902664-21-000523 Dispute this row
Martin D. Hoe Common Stock, $0.0001 par value4.995,707,107— Filed 2021-01-26SC 13G/AAmendment 1Read from the cover page textOpen filing 0000902664-21-000523 Dispute this row
Altium Capital Management, LP Common Stock, par value $0.0001 per share5.8538,090— Filed 2020-04-10SC 13GRead from the cover page textOpen filing 0001387131-20-003816 Dispute this row
Altium Growth Fund, LP Common Stock, par value $0.0001 per share5.8538,090— Filed 2020-04-10SC 13GRead from the cover page textOpen filing 0001387131-20-003816 Dispute this row
Altium Growth GP, LLC Common Stock, par value $0.0001 per share5.8538,090— Filed 2020-04-10SC 13GRead from the cover page textOpen filing 0001387131-20-003816 Dispute this row
Bryan Ezralow Common Stock, $0.0001 par value per share4.97555,641— Filed 2020-04-08SC 13G/AAmendment 4Read from the cover page textOpen filing 0001753926-20-000082 Dispute this row
Empery Debt Opportunity Fund, LP Common Stock, $0.0001 par value5.56511,185— Filed 2020-04-07SC 13GRead from the cover page textOpen filing 0000902664-20-001755 Dispute this row
Empery Asset Management, LP Common Stock, $0.0001 par value5.85538,090— Filed 2020-04-07SC 13GRead from the cover page textOpen filing 0000902664-20-001755 Dispute this row
Ryan M. Lane Common Stock, $0.0001 par value5.85538,090— Filed 2020-04-07SC 13GRead from the cover page textOpen filing 0000902664-20-001755 Dispute this row
Martin D. Hoe Common Stock, $0.0001 par value5.85538,090— Filed 2020-04-07SC 13GRead from the cover page textOpen filing 0000902664-20-001755 Dispute this row
Arena Origination Co., LLC Common Stock, par value $0.0001 per share9.99905— Filed 2020-03-31SC 13GRead from the cover page textOpen filing 0001213900-20-008171 Dispute this row
Arena Special Opportunities Fund, LP Common Stock, par value $0.0001 per share9.99595— Filed 2020-03-31SC 13GRead from the cover page textOpen filing 0001213900-20-008171 Dispute this row
Westaim Origination Holdings, Inc. Common Stock, par value $0.0001 per share9.99905— Filed 2020-03-31SC 13GRead from the cover page textOpen filing 0001213900-20-008171 Dispute this row
Arena Special Opportunities Fund (Onshore) GP, LLC Common Stock, par value $0.0001 per share9.99595— Filed 2020-03-31SC 13GRead from the cover page textOpen filing 0001213900-20-008171 Dispute this row
Arena Investors, LP Common Stock, par value $0.0001 per share9.991,500— Filed 2020-03-31SC 13GRead from the cover page textOpen filing 0001213900-20-008171 Dispute this row
Arena Investors GP, LLC Common Stock, par value $0.0001 per share9.991,500— Filed 2020-03-31SC 13GRead from the cover page textOpen filing 0001213900-20-008171 Dispute this row
Bryan Ezralow Common Stock, $0.0001 par value per share5.6624,349— Filed 2020-03-03SC 13G/AAmendment 3Read from the cover page textOpen filing 0001753926-20-000028 Dispute this row
Bryan Ezralow Common Stock, $0.0001 par value per share2.03204,349— Filed 2020-02-10SC 13G/AAmendment 2Read from the cover page textOpen filing 0001753926-20-000014 Dispute this row
Bryan Ezralow 1994 Trust u/t/d December 22, 1994 Common Stock, $0.0001 par value per share2.03204,349— Filed 2020-02-10SC 13G/AAmendment 2Read from the cover page textOpen filing 0001753926-20-000014 Dispute this row
Larry Spitcaufsky Common Stock, Par Value $0.0001 per share6.29663,473— Filed 2019-11-21SC 13D/AAmendment 6Read from the cover page textOpen filing 0001140361-19-021103 Dispute this row
Larry Spitcaufsky Common Stock, Par Value $0.0001 per share22.111,063,473— Filed 2019-09-03SC 13D/AAmendment 5Read from the cover page textOpen filing 0001140361-19-015999 Dispute this row
Larry Spitcaufsky Common Stock, Par Value $0.0001 per share22.111,063,473— Filed 2019-05-23SC 13D/AAmendment 4Read from the cover page textOpen filing 0001140361-19-009731 Dispute this row
Bryan Ezralow Common Stock, $0.0001 par value per share6.7202,749— Filed 2018-02-13SC 13G/AAmendment 1Read from the cover page textOpen filing 0001615774-18-001087 Dispute this row
Bryan Ezralow 1994 Trust u/t/d December 22, 1994 Common Stock, $0.0001 par value per share6.7202,749— Filed 2018-02-13SC 13G/AAmendment 1Read from the cover page textOpen filing 0001615774-18-001087 Dispute this row
Larry Spitcaufsky Common Stock, Par Value $0.0001 per share18.75552,292— Filed 2017-09-05SC 13D/AAmendment 3Read from the cover page textOpen filing 0001140361-17-034226 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

3,104,499 filings read, dated 1980-01-02 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015258,595
2016246,472
2017244,814
2018245,575
2019238,619
2020249,093
2021274,850
2022257,922
2023253,676
2024261,106
2025235,525
2026263,830

Filings made before the SEC required XML are listed, not extracted.

Back to Chanticleer Holdings, Inc.